Self-Targeted, Shape-Assisted, and Controlled-Release Self-Delivery Nanodrug for Synergistic Targeting/Anticancer Effect of Cytoplasm and Nucleus of Cancer Cells
Source abstract
Abstract
We constructed 10-hydroxycamptothecin (CPT) "nanodrugs" with functionalization of lipid-PEG-methotrexate (MTX) to prepare high-drug-loaded, and sustained/controlled-release MTX-PEG-CPT nanorods (NRs), in which MTX drug itself can serve as a specific "targeting ligand". The self-targeted nanodrug can codeliver both CPT and MTX drugs with distinct anticancer mechanisms. Furthermore, MTX-PEG-CPT NRs significantly reduced burst release, improved blood circulation and tumor accumulation, enhanced cellular uptake, and synergistically increased anticancer effect against tumor cells compared with MTX-PEG-CPT nanospheres (NSs) and either both free drugs or individual free drug. Therefore, the synergistic targeting/therapeuticy nano-multi-drug codelivery assisted by shape design may advantageously offer a promising new strategy for nanomedicine.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomaterials and Department of Materials Science and Engineering, College of Materials, §Fujian Provincial Key Laboratory of Fire Retardant Materials, College of Materials, ⊥Department of Chemistry, College of Chemistry & Chemical Engineering, ∥Department of Pharmacy, School of Pharmaceutical Science, and #The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen 361005, China
Funding
National Natural Science Foundation of China · Fujian Province
References (28)
Show source-provided references
1. Garcia-Carbonero R. · Clin. Cancer Res. · 2002 · 8 · 641
2. 10.1021/ja311598310.1021/ja3115983 ↗
3. 10.1021/nn900568610.1021/nn9005686 ↗
4. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
5. 10.1021/ja505212y10.1021/ja505212y ↗
6. 10.1021/mp500744m10.1021/mp500744m ↗
7. 10.2147/IJN.S59510.2147/IJN.S595 ↗
8. 10.1083/jcb.132.1.3510.1083/jcb.132.1.35 ↗
9. 10.1021/mp500606810.1021/mp5006068 ↗
10. 10.1039/C4TB00499J10.1039/C4TB00499J ↗
11. 10.1021/acsami.5b0168510.1021/acsami.5b01685 ↗
12. 10.1002/adma.20080000410.1002/adma.200800004 ↗
13. 10.1038/nnano.2007.7010.1038/nnano.2007.70 ↗
14. 10.1002/smll.20110049710.1002/smll.201100497 ↗
15. 10.1038/mt.2008.12710.1038/mt.2008.127 ↗
16. 10.1021/mp500464b10.1021/mp500464b ↗
17. 10.1073/pnas.130834511010.1073/pnas.1308345110 ↗
18. 10.1016/j.jconrel.2007.03.02210.1016/j.jconrel.2007.03.022 ↗
19. 10.1021/mp900022m10.1021/mp900022m ↗
20. 10.1038/nmat301410.1038/nmat3014 ↗
21. 10.1038/nbt.154910.1038/nbt.1549 ↗
22. 10.1038/nbt.228410.1038/nbt.2284 ↗
23. 10.1038/nrc189110.1038/nrc1891 ↗
24. 10.1038/273545a010.1038/273545a0 ↗
25. 10.1021/acsami.5b0503810.1021/acsami.5b05038 ↗
26. 10.1016/S0168-3659(97)00236-810.1016/S0168-3659(97)00236-8 ↗
27. 10.1038/nbt120410.1038/nbt1204 ↗
28. 10.1016/j.canlet.2004.02.00410.1016/j.canlet.2004.02.004 ↗